This early-stage study tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes vision loss. About 30 participants will receive eye injections and be monitored for 26 weeks to check…
Phase: PHASE1, PHASE2 • Sponsor: Michelle Abou-Jaoude • Aim: Disease control
Last updated May 26, 2026 12:08 UTC